
CDISC Public Webinar – Standards Updates and Additions

13 OCT 2016



Agenda

Ebola TA Public Review

- Rhonda Facile, MS, Vice President, Standards Development
- Maura Kush, CDISC Specialist and Data Standards Consultant, Pharmastat
- Shannon Labout CCDM, Vice President of Education, CDISC
- Bess LeRoy, Metadata Engineer, CDISC
- Jon Neville, PSM, Program Director, Data Standards and Management
- Diane Wold, Senior Director, Standards Development and Modeling, CDISC

Malaria TA Public Review

- Lesley Workman, Scientific Coordinator, Division of Clinical Pharmacology, University of Cape Town
- Bess LeRoy, Metadata Engineer, CDISC
- Alana St. Clair, Associate Project Manager, CDISC
- Jon Neville, PSM, Program Director, Data Standards and Management
- Diane Wold, Senior Director, Standards Development and Modeling, CDISC
- Rhonda Facile, MS, Vice President, Standards Development

Question & Answer

- 'Panelist': Question
 OR
- 'Presentation': Question

Examples:

Maura: Where can I find the Ebola TA Guide? Malaria Team: Are there known issues with the Malaria TA analysis section?



EVD Therapeutic Area User Guide

Maura Kush EVD Project Co-Lead

Panelists: Bess LeRoy, Diane Wold, Jon Neville, Shannon Labout

Strength through Collaboration



© CDISC 2016

Agenda

- Background on project and participants
- Scope and gap analysis
- Additional requirements
- Known issues and focus of public review
- Public review dates

Background

- Sense of urgency during the Ebola outbreak
- Collaboration with the Oxford University Clinical Research Unit (OUCRU) in Vietnam
- Needed to address certain challenges of EVD studies
 - Outbreak setting
 - Many different stakeholders, all with different use cases and research goals
- Led to a gap analysis and a narrowed scope with more focused development



EVD TAUG Scope

- Majority based on data elements from WHO CORE case report form (CRF),
 - Includes some epidemiological and vaccination data
 - Does not include pediatric or survivor data, or vaccine trials as a whole
 - Does not include ADaM
- Describes how to represent the most common data for Ebola studies

EVD TAUG Documentation

- SDTM v1.4
- SDTMIG v3.2
- SDTMIG AP
- Controlled Terminology
- CDASH v1.1
- Influenza v2.0, Tuberculosis v2.0, Malaria v1.0



Ebola Table of Contents

- **1** INTRODUCTION
- 1.1 How to Read this Document
- 1.2 Organization of this Document
- 1.3 Known Issues
- 2 SUBJECT AND DISEASE CHARACTERISTICS
- 2.1 Subject Characteristics
- 2.2 EVD Exposure and Risk Factors
- 2.2.1 Environmental Risk Factors
- 2.2.2 Source Case Investigation
- 2.2.3 Contact Case Investigation

3 DISEASE ASSESSMENTS

- 3.1 Daily Assessment of Signs and Symptoms
- 3.2 Diagnosis and Confirmation of Infection
- 3.3 Immune Response
- 3.4 Reactogenicity
- 3.5 Questionnaires, Ratings, and Scales

4 ROUTINE DATA

- 4.1 Concomitant Medications
- 4.2 Measured/Estimated Weight
- 4.3 Medication Redosing
- 4.4 Reproductive Findings
- 4.5 End of Study/Early Termination

Threshold Cycle CDASH CRF and SDTM Examples

m	b.xpt	:xpt																
R	low	STUDYID	DOMAIN	USUBJID	SPDEVID	MBSEQ	MBREFID	MBTESTCD	MBTEST	MBTSTDTL	MBORRES	MBSTRESC	MBSPEC	MBMETHOD	VISITNUM	VISIT	MBDTC	CTVAL
	1	EVD123	MB	EVD01-	ABI7500	1	SAMP0101	ZEBOV	Zaire	IDENTIFICATION	NECATIVE			QUANTITATIVE REVERSE TRANSCRIPTASE	1	VISIT	2014-	12
	'	EVD125	IVID	01	ADI7 300	1	SAMPUTUT	ZEBUV	Ebolavirus	IDENTIFICATION	NEGATIVE	NEGATIVE	BLOOD	POLYMERASE CHAIN REACTION		1	08-06	42
Г	~	EVD123	MB	EVD01-	ABI7500	0	SAMP0102	ZEBOV	Zaire	IDENTIFICATION	DOCITIVE	DOCITIVE	BLOOD	QUANTITATIVE REVERSE TRANSCRIPTASE	4	VISIT	2014-	26
	2	EVD123	IVID	02	ADI7500	2	SAMPUTUZ	ZEBUV	Ebolavirus	IDENTIFICATION	POSITIVE	POSITIVE	BLOOD	POLYMERASE CHAIN REACTION		1	08-06	20
	2	EVD123	MB	EVD01-	ABI7500	2	SAMD0402	ZEBOV	Zaire	IDENTIFICATION			BLOOD	QUANTITATIVE REVERSE TRANSCRIPTASE	4	VISIT	2014-	44
	ັ	EVD125	IVID	03	ABI7 300	3	SAMP0103	ZEBUV	Ebolaviurs	IDENTIFICATION	NEGATIVE	NEGATIVE	BLOOD	POLYMERASE CHAIN REACTION		1	08-06	41

MB NSV Metadata

Variable	Label	Туре	Role	Origin
CTVAL	Threshold Cycle Value	text	Non-Standard Variable Qualifier	CRF

Date MBDAT MBDTC dd-MON-yyyy	mm/dd/yyyy
Time MBTIM MBDAT hh:mm:ss	:
Method MBMETHOD Pre-specified	qRT-PCR
Test Name MBTEST Pre-specified	ZEBOV
Device Type DIVAL where DIPARM = 'Device Type'	
Specimen Type MBSPEC	BloodSerumOther
Specimen Type Other	
Accession Number	
Kit Number	
Result MBORRES	PositiveNegativeUnknown
Threshold Cycle Result SUPPMB.QVAL where QNAM = 'CTVAL'	cycles

Sponsors are responsible for understanding and implementing CDISC Controlled Terminology where applicable.

Viral Identification

Origin

CRF

- Historically viral identification shown in LB
- This has changed, and this guide has examples that show it in MB where MBTSTDTL='IDENTIFICATION'

 mb.xp mb.xp 																	
· · · ·		DOMAIN	USUBJID	SPDEVID	MBSEQ	MBREFID	MBTESTCD	MBTEST	MBTSTDTL	MBORRES	MBSTRESC	MBSPEC	MBMETHOD	VISITNUM	VISIT	MBDTC	CTVAL
1	EVD123	MB	EVD01- 01	ABI7500	1	SAMP0101	ZEBOV	Zaire Ebolavrus	IDENTIFICATION	NEGATIVE	NEGATIVE	BLOOD	QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION	1	VISIT 1	2014- 08-06	42
2	EVD123	MB	EVD01- 02	ABI7500	1	SAMP0102	ZEBOV	Zaile Ebolavirus	IDENTIFICATION	POSITIVE	POSITIVE	BLOOD	QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION	1	VISIT 1	2014- 08-06	26
3	EVD123	MB	EVD01- 03	ABI7500	1	SAMP0103	ZEBOV	Zaire Ebolaviure	IDENTIFICATION	NEGATIVE	NEGATIVE	BLOOD	QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION	1	VISIT 1	2014- 08-06	41
MB N	SV Metada	ta												·			

Variable Label

CTVAL


Type | Role

Non-Standard Variable Qualifier

Threshold Cycle Value text

New Domain

- ER (Environmental Risk Factors)
 - Out for review with SDTM v3.3 Batch 3
 - Events observation class domain for data collected on potential exposures to, or diseases by way of environmental contact or through participation in activities associated with risk



er.xpt

Row	STUDYID	DOMAIN	USUBJID	ERSEQ	ERTERM	ERCAT	ERDTC	ERSTDTC	ERENDTC	CNCTYP
1	VHF-2015	ER	VHF-15-101	1	Exposure to EVD	SOURCE CASE	2015-02-05	2015-01-02	2015-01-10	Touched or shared linens, clothes, dishes or utensils of case

ER NSV Metadata

Variable		Туре		Origin
CNCTYP	Contact Type	text	Non-Standard Record Qualifier	CRF



Known Issues

- Non Standard Variables (NSV) proposed changes
- Signs and symptoms in Findings About (FA)
- Personally identifying information in Subject Characteristics (SC)
- Controlled Terminology is not final
- NHOID='Zaire Ebola Virus' provides enough detail without an OI domain
- Measured/Estimated Weight



Public Review

- Public Review comments due: 4 November 2016
- Public review is a key part of the standards development process.

We look forward to getting your feedback!



DEVELOPING A DATA STANDARD FOR UNCOMPLICATED MALARIA

Clinical Data Interchange Standards Consortium (CDISC) WorldWide Antimalarial Resistance Network (WWARN)

- WWARN collaboration
- 13 October, 2016

www.wwarn.org

Twitter: @WWARN





Topics

- Project Scope Alana
- Project Background Lesley
- New Domains and Examples Bess
- Known issues Bess
- Public review

Malaria Standards Development Project Scope

- Describe how to represent the most common data for uncomplicated malaria studies
 - Deliverables: CDISC Therapeutic Area User Guide, concept maps, CDASH compliant CRF, SDTM examples and controlled terminology
- Based on data elements from WWARN case report form (CRF)
 - Includes examples for parasite genotyping, combination therapy, dosing with food and post dose vomiting, among others
 - Includes an analysis considerations section



Project Mission:

To support efficient, scientifically valid generation and reporting of clinical malaria data to streamline antimalarial development, regulatory submission and post-marketing research, as well as enable data sharing, comparison and aggregation.

Aim:

Consensus-based development of a single, freely available data standard to ensure the consistent use of existing CDISC standards, and to facilitate alignment and development of new standards for the electronic acquisition, exchange, submission and archiving of clinical malaria data collection, analysis and reporting

Scope (Year 1):


- Uncomplicated falciparum malaria
- Uncomplicated vivax malaria

Preventive treatment (e.g SMC, IPT, MDA), Induced Blood Stage Malaria (Human Challenge Studies), severe malaria to follow, as needed



Role of WWARN

- <u>Facilitate</u> the development of a CDISC data standard for malaria.
- Enable data sharing
- Conduct pooled data analyses to quantify effects
- Provide the (long-term) storage infrastructure and maintaining of the antimalarial data repository / archive



The role of stakeholders

Current Stakeholders include:

- CDISC, C-PATH
- WWARN members
- WHO GMP / TDR
- BMGF
- GHT, LSTM,
- Pharma:
 - o GlaxoSmithKline
 - Medicines for Malaria Venture
 - o Merck
 - o Novartis
 - o Sanofi
 - o Shin Poon
 - o Sigma Tau
 - o Takeda
 - o UCB

Review draft data standards

Share relevant experience:

- Recent CRF templates / Database Structures / Statistical Analysis Plans
- Identification of critical issues in regulatory submissions.



CDASH CRF and SDTM Examples



New Domain #1

• ER – Environmental Risk Factors

Household Characteristics (ER)	Occur EROCCUR
Has the Malaria Control Program performed Indoor Residual Insecticide Spraying (IRS) of your home in the last 12 months?	O Yes
EHTERM=Indoor residual insecticide spraying	O No
Did you sleep under an insecticide treated bed-net last night?	O Yes
ERTERM=Sleep under an insecticide treated bed-net	O No

Row 1: Shows that subject ABC-001's household had indoor residual insecticide spraying within the last 12 months (EREVLINT).

Row 2: Shows that subject ABC-001 slept under an insecticide treated bed-net last night (EREVINTX). MAL-112 - Getting issue details... STATUS

Row	STUDYID	DOMAIN	USUBJID	ERSEQ	ERTERM	ERCAT	ERPRESP	EROCCUR	ERDTC	EREVLINT	EREVINTX
1	ABC	ER	ABC-001	1	Indoor residual insecticide spraying	HOUSEHOLD CHARACTERISTICS	Y	Y	2015- 05-15	-P12M	
2	ABC	ER	ABC-001	2	Sleep under an insecticide- treated bed net	HOUSEHOLD CHARACTERISTICS	Y	Y	2015- 05-15		LAST NIGHT



er.xpt

New Domain #2

• SI – Site Summary

si.xpt

Row	STUDYID	DOMAIN	SITEID	SISEQ	SIGRPID	SIPARMCD	SIPARM	SIVAL	SIVALNF	SIVALCD	SIVCDREF	SIVCDVER
1	ABC	SI	123	1		TRANINTY	Transmission Intensity	HIGH		C22222	CDISC	2016-03-25
2	ABC	SI	345	1		TRANINTY	Transmission Intensity	MEDIUM		C22222	CDISC	2016-03-25
3	ABC	SI	567	1		TRANINTY	Transmission Intensity	HIGH		C22222	CDISC	2016-03-25

Known Issues

- Representation of combination therapy data
 - We show an example using a combination of EC and EX as a possible solution. This is different from the modeling strategy used in the TAUG-TB (example using a combination of EX and FA).
- Use of --EVINTX for representation of timing around food intake and post dose vomiting
 - There is disagreement regarding whether or not this is an appropriate use of –EVINTX.

© CDISC 2016

30-Day Public Review

- Public Review dates:
 - October 6 November 6
- Public review is a <u>key</u> part of the standards development process.

We look forward to getting your feedback!










CDISC Online Education & Event Updates

John Ezzell, CDISC



Upcoming Webinars

Presenter	Торіс	Webinar Date
John Owen, Project Manager, CDISC	Prostate Cancer TA Public Review	19 OCT 2016
Dr. Lauren Becnel, CDISC Anthony Chow, Sr. Manager, CDISC	SHARE Deep Dive	20 OCT 2016
Dr. Lauren Becnel, CDISC	BRIDG Overview	TBD

Webinar details and registration at <u>www.cdisc.org/webinars</u>

© CDISC 2016

ISC

Standard currently out for review

- <u>Terminology Call for Public</u> <u>Review Package 28</u> Comments Due by: October 7, 2016
- Draft Content SDTMIG v3.3 Batch 3 Now Available for Public Review Comments Due by: October 21, 2016
- <u>New Draft Ebola v1 Now Available</u> <u>for Public Review</u> Comments Due by: November 4, 2016



UPCOMING NORTH AMERICA PUBLIC COURSES

Location	Dates	Courses Offered:	Discount period ends:	Late fees kick(ed) in:	Host
Miami, FL	23-27 Jan 2017	SDTM, CDASH, ADaM Primer, ADaM T&A	23 Oct 2016	23 Dec 2106	CLINICAL RESEARCH OPTIMIZED
Raleigh, NC	27 Feb – 3 Mar 2017	SDTM, CDASH, ADaM Primer, ADaM T&A	28 Nov 2016	28 Jan 2017	
Audubon, PA	3-7 Apr 2017	SDTM, CDASH, ADaM Primer, ADaM T&A, CT, Define-XML	3 Jan 2017	3 Mar 2017	BIOCLINICA® SEE MORE CLEARLY
Toronto, ON	5-9 June 2017	SDTM, CDASH, ADaM Primer, ADaM T&A, Define-XML	6 Mar 2017	5 May 2017	MCDOUGALL SCIENTIFIC INSIGHTS YOU CAN TRUBY

Visit <u>cdisc.org/public-courses</u> for information on other CDISC Public Training events.



UPCOMING EUROPE PUBLIC COURSES

Location	Dates	Courses Offered:	Discount period ends	Late fees kick(ed) in:	Host
Basel, Switzerland	7-11 Nov 2016	SDTM, ADaM Primer, ADaM T&A, Define-XML	Ended	7 Oct	ACTELION
London, UK	24-28 Apr 2017	TBD	TBD	TBD	

Visit <u>cdisc.org/public-courses</u> for information on other CDISC Public Training events.



UPCOMING ASIA PUBLIC COURSES


Location	Dates	Courses Offered	Discount period ends:	Late fees kick(ed) in:	Host
Beijing, China	18-21 Oct 2016	SDTM, CDASH, ADaM Primer, ADaM T&A, ODM, Define-XML	Ended	None	
Shanghai, China	24-27 Oct	SDTM, CDASH, ADaM Primer, ADaM T&A, ODM, Define-XML	Ended	None	PAREXEL
Tokyo, Japan	5-9 Dec	SDTM, CDASH, ADaM Primer, ADaM T&A, ODM, Define-XML	Ended	5 Nov	Croit

Visit <u>cdisc.org/public-courses</u> for information on other CDISC Public Training events.



CDISC Online Training Production Update

- Just Released
 - ADaM Module 4 Online Training
 - Mini-Training: Ensuring USUBJID is Unique for an Individual in an Application



Online Courses in Development
TA Alzheimer's
TA QT Studies
TA Vaccines
TA Prostate Cancer
TA Rheumatoid Arthritis
TA Pain
ADaM Modules 5-8
CT Module 1 & 2
Define-XML



Any more questions?

Thank you for attending this webinar.

CDISC's vision is to: Inform Patient Care & Safety Through Higher Quality Medical Research

Strength through collaboration.



CDISC Members Drive Global Standards

Thank you for your support!



Learn CDISC from CDISC! Authoritative. Global. Vendor neutral.



© CDISC 2016